Loading clinical trials...

Preventive Effects of Bosentan on the Systemic Cardiovascular Consequence of Sleep Apnea | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Preventive Effects of Bosentan on the Systemic Cardiovascular Consequence of Sleep Apnea

Cardiovascular Consequences of Obstructive Sleep Apnea (OSA): Role of Endothelin and Preventive Effects of Bosentan

NCT00777985•University Hospital, Grenoble

View on ClinicalTrials.gov

Summary

The study will compared the effects of bosentan, an endothelin receptor antagonist, and nasal continuous positive airway pressure (nCPAP), obstructive sleep apnea current reference treatment, on diastolic blood pressure in untreated mildly hypertensive sleep apnea patients. The hypothesis is that blocking endothelin receptors with a drug will have the same systemic blood pressure lowering effect than nCPAP in sleep apnea patients.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Documented obstructive sleep apnea
•with untreated mild systemic hypertension

Exclusion Criteria

•pregnancy or lactation
•daytime alveolar hypoventilation
•severe arterial hypertension (systolic pressure \> 180 mmHg; diastolic pressure \> 110 mmHg)
•treatment with anti-hypertensive drugs
•cardiovascular disorder other than mild hypertension
•severe daytime sleepiness (score on the EPWORTH sleepiness scale ≥15) or at-risk occupation
•contra-indication to nCPAP treatment
•known allergy to bosentan
•active treatment with a drug whose efficacy is reduced by cytochromes P450, 2C9, 3A4 and2C19 isoenzyme activation
•active treatment with a drug acting on systemic arterial blood pressure or endothelial function
+1 more criteria

Locations (1)

CHU de Grenoble

Grenoble, France

Key Dates

Start Date

December 1, 2007

Primary Completion Date

January 1, 2012

Completion Date

January 1, 2012

Last Updated

December 22, 2025

Enrollment

ACTUAL participants

Conditions

Obstructive Sleep ApneaHypertension

Interventions

bosentan

DRUG

nasal continuous positive airway pressure (CPAP)

DEVICE

OSA Risk Level in Dental Patients and Correlation With Complications After General Anesthesia

NCT06430957

Obstructive Sleep Apnea Risk ManagementPostoperative Complications+2 more

View study

RECRUITING

Natural History of Noncirrhotic Portal Hypertension

NCT02417740

Cystic FibrosisImmunologic Deficiency Syndrome+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 22, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Preventive Effects of Bosentan on the Systemic Cardiovascular Consequence of Sleep Apnea

Inclusion Criteria

Exclusion Criteria

OSA Risk Level in Dental Patients and Correlation With Complications After General Anesthesia

Natural History of Noncirrhotic Portal Hypertension

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension

Mobile Cued Adherence Therapy (mCAT) for Blood Pressure Medication

Digital-supported Orofacial Myofunctional Therapy in OSA